Supporting the role of EZH2 in prostate cancer progression, a study by Labbé and colleagues found that prostate cancer patients with high EZH2 and DNA topoisomerase 2 alpha (TOP2A) expression had a distinct transcriptome that was coupled with shorter time to biochemical recurrence and progression to metastatic disease (90). This evidence concerns the gene EZH2 and prostate cancer.